Skip to content
Finance Investment, Medical Health Aged Care

Medicinal cannabis company Little Green Pharma (ASX:LGP) records record quarterly revenue and cash receipts

Little Green Pharma 3 mins read

RECORD REVENUE AND CASH RECEIPTS FOR QUARTER AND FINANCIAL YEAR,

POSITIVE OPERATING CASHFLOW FOR FY24 OF $0.5 MILLION

 

Highlights 

  • Record quarterly cash receipts of $8.1 million, up over 50% on previous quarter and over 20% on previous corresponding period
  • Record quarterly revenue of $7.3 million (unaudited), up 34% on previous quarter and over36% on previous corresponding period
  • Record revenue of $25.6million (unaudited) for FY24, up nearly 30% on previous financial year resulting in positive operating cashflow of $0.5million for financial year
  • Cannabis legalised in Germany with its removal from the Narcotics List
  • Cash in bank of $5.0 million at 31 March 2024 up from $3.7 million at 31 December 2023

To view a copy of the company's Quarterly Activities Report lease click here

About Little Green Pharma

Little Green Pharma is a global, vertically integrated and geographically diverse medicinal cannabis business with operations from cultivation and production through to manufacturing and distribution.

The Company has two global production sites for the manufacture of its own-branded and white-label ranges of GMP-grade medicinal cannabis products, being a Danish production facility with a potential nameplate capacity of over 30 tonnes of cannabis biomas per annum and a West Australia premium indoor GMP production facility specialising in premium hand-crafted cannabis strains.

Little Green Pharma products comply with all required Danish Medicines Agency and Therapeutic Goods Administration regulations and testing requirements. With a growing range of products containing differing ratios of active ingredients, Little Green Pharma supplies medical-grade cannabis products to Australian, European and overseas markets.

The Company has a strong focus on patient access in the emerging global medicinal cannabis market and is actively engaged in promoting education and outreach programs, as well as participating in clinical investigations and research projects to develop innovative new delivery systems.

For more information about Little Green Pharma go to: www.littlegreenpharma.com

 


About us:

About Little Green Pharma Little Green Pharma is a global, vertically integrated and geographically diverse medicinal cannabis business with operations from cultivation and production through to manufacturing and distribution. The Company has two global production sites for the manufacture of its own-branded and white-label ranges of GMP-grade medicinal cannabis products, being a Danish production facility with a potential nameplate capacity of over 30 tonnes of cannabis biomas per annum and a West Australia premium indoor GMP production facility specialising in premium hand-crafted cannabis strains. Little Green Pharma products comply with all required Danish Medicines Agency and Therapeutic Goods Administration regulations and testing requirements. With a growing range of products containing differing ratios of active ingredients, Little Green Pharma supplies medical-grade cannabis products to Australian, European and overseas markets. The Company has a strong focus on patient access in the emerging global medicinal cannabis market and is actively engaged in promoting education and outreach programs, as well as participating in clinical investigations and research projects to develop innovative new delivery systems. For more information about Little Green Pharma go to: www.littlegreenpharma.comAbout Little Green PharmaLittle Green Pharma is a global, vertically integrated and geographically diverse medicinal cannabis business with operations from cultivation and production through to manufacturing and distribution.The Company has two global production sites for the manufacture of its own-branded and white-label ranges of GMP-grade medicinal cannabis products, being a Danish production facility with a potential nameplate capacity of over 30 tonnes of cannabis biomas per annum and a West Australia premium indoor GMP production facility specialising in premium hand-crafted cannabis strains.Little Green Pharma products comply with all required Danish Medicines Agency and Therapeutic Goods Administration regulations and testing requirements. With a growing range of products containing differing ratios of active ingredients, Little Green Pharma supplies medical-grade cannabis products to Australian, European and overseas markets.The Company has a strong focus on patient access in the emerging global medicinal cannabis market and is actively engaged in promoting education and outreach programs, as well as participating in clinical investigations and research projects to develop innovative new delivery systems.For more information about Little Green Pharma go to: www.littlegreenpharma.comAbout Little Green PharmaLittle Green Pharma is a global, vertically integrated and geographically diverse medicinal cannabis business with operations from cultivation and production through to manufacturing and distribution.The Company has two global production sites for the manufacture of its own-branded and white-label ranges of GMP-grade medicinal cannabis products, being a Danish production facility with a potential nameplate capacity of over 30 tonnes of cannabis biomas per annum and a West Australia premium indoor GMP production facility specialising in premium hand-crafted cannabis strains.Little Green Pharma products comply with all required Danish Medicines Agency and Therapeutic Goods Administration regulations and testing requirements. With a growing range of products containing differing ratios of active ingredients, Little Green Pharma supplies medical-grade cannabis products to Australian, European and overseas markets.The Company has a strong focus on patient access in the emerging global medicinal cannabis market and is actively engaged in promoting education and outreach programs, as well as participating in clinical investigations and research projects to develop innovative new delivery systems.For more information about Little Green Pharma go to: www.littlegreenpharma.com


Contact details:

David Tasker 

Chapter One Advisots

E: dtasker@chapteroneadvisors.com.au 

M: 0433 112 936

Media

More from this category

  • Medical Health Aged Care
  • 20/03/2025
  • 06:05
Royal Australian College of GPs

Foundation for GP research will build healthier communities

The Royal Australian College of GPs (RACGP) yesterday relaunched its Australian General Practice Research Foundation with a new focus on innovation and impact to improve patient care and health outcomes. The Foundation’s patron Professor Michael Kidd AO, a globally recognised leader in general practice and primary care, will support the Foundation’s mission to champion excellence and innovation in general practice research. Professor Kidd AO said: “General practice impacts the lives of millions of Australians every year, yet general practice research has often been underfunded and undervalued. “This Foundation is our chance to change that and ensure that all GPs have…

  • Medical Health Aged Care
  • 20/03/2025
  • 03:10
TruMerit

TruMerit and International Council of Nurses Launch Collaborative to Propel Nursing Workforce Development Worldwide

NEW YORK CITY, NEW YORK / ACCESS Newswire / March 19, 2025 / TruMerit™ (formerly CGFNS International) and the International Council of Nurses (ICN) have announced the launch of a jointly operated clearinghouse for research, data, and policy solutions on the world's nursing workforce.TruMerit and International Council of NursesThe new collaborative, the Global Nursing Workforce Centre, will address the absence of a central repository to aggregate and analyze this knowledge and highlight gaps. It will mobilize evidence-driven capacity building strategies and policy solutions aimed at strengthening the global nursing workforce and, with that, the quality of patient care across diverse…

  • Finance Investment
  • 20/03/2025
  • 00:01
SenateSHJ

Corporate Crises Cost Big: New hard-hitting data reveals financial impact of reputation disasters

World-first Crisis Index 300 database reveals share prices plummet by 35.2% on average following a crisis and suffer a 68.6% average drop in earnings per share (EPS). Road to recovery is long, with companies averaging 425 days to regain pre-crisis stock levels. Nearly a third of the companies’ share prices have yet to recover - 33 companies have delisted due to bankruptcy, acquisitions, or privatisations. Sydney, 20 March 2025: Corporate share prices drop an average 35.2% and take a staggering 427 days on average to recover from a crisis while some never do, world-first research by SenateSHJ reveals. When a…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.